01—Abstract
Summary
Summary of the 10-Q filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported second-quarter 2025 results (three months ended June 28, 2025) with total revenue of $1,032.1 milliona, up 0.6% from $1,026.1 million a year earlier, while operating income fell to $100.1 million from $151.7 million, and net income attributable to the company's common shareholders decreased to $52.3 million from $90.0 million.
For the six months, revenue declined 1.0% to $2,016.3 million and operating income dropped to $174.8 millionb from $277.6 million. The filing attributes the profit decline mainly to accelerated amortization of certain CDMO client relationships after loss of key customers, higher restructuring and asset impairment charges, and higher third-party legal and advisory costs. DSA revenue declined on cautious client spending, with DSA backlog at $1.9 billion versus $2.0 billion at December 28, 2024.
Cash flow from operations improved to $376.3 millionc for the six months from $323.4 million, while the company repurchased $350.0 million of stock under its $1.0 billion program and had $549.3 million remaining authorization at quarter end. Total debt and finance leases rose to $2.35 billion, and the revolving facility balance increased to $813.0 million from $714.9 million. The company disclosed a Cooperation Agreement with Elliott Investment Management and a comprehensive strategic review overseen by the Board's Strategic Partnership and Capital Allocation Committee, with no assurance the review will produce a transaction.
The filing also details ongoing exposure from the non-human primate supply chain matters. The DOJ grand jury and parallel civil investigations were closed, USFWS cleared the Cambodian NHP shipments for entry, and the SEC investigation, a securities class action on appeal, and two stayed derivative lawsuits remain pending, with the company unable to estimate potential losses. The company also cites restructuring actions expected to yield about $225 milliond in annualized cost savings, of which about $175 million affects fiscal 2025.
02—Key points
Key Highlights
- Total revenue for Q2 2025 was $1,032.1 million, up 0.6% year over year; six-month revenue was $2,016.3 million, down 1.0%.
- Operating income fell to $100.1 million in Q2 2025 from $151.7 million, with operating margin of 9.7% versus 14.8%, driven by accelerated CDMO client relationship amortization, restructuring charges, and legal and advisory costs.
- Manufacturing operating income dropped to $12.1 million from $37.2 million in Q2, largely due to $46.3 million of amortization expense versus $10.8 million a year earlier.
- Net income attributable to common shareholders was $52.3 million in Q2 2025 versus $90.0 million in Q2 2024; diluted EPS was $1.06 versus $1.74.
- DSA backlog declined slightly to $1.9 billion from $2.0 billion, reflecting cautious client spending on drug pipelines and budgets.
- Operating cash flow rose to $376.3 million for the six months from $323.4 million; $350.0 million was spent repurchasing 2.1 million shares, leaving $549.3 million under the repurchase authorization.
- Restructuring actions are expected to generate about $225 million of annualized cost savings, with about $175 million affecting fiscal 2025.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 6, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $1.03B$1.03B | +0.6% |
| SG&A Expenses | $191.55M$169.79M | +12.8% |
| Operating Income | $100.13M$151.65M | −34.0% |
| Net Income | $52.33M$89.99M | −41.9% |
| EPS (Basic) | $1.06$1.75 | −39.4% |
| EPS (Diluted) | $1.06$1.74 | −39.1% |
| Shares Outstanding (Basic) | 49.15M51.55M | −4.7% |
| Shares Outstanding (Diluted) | 49.32M51.85M | −4.9% |
05—Questions
Frequently Asked Questions
Why did operating income decline so sharply in the second quarter?
The filing attributes the decline to accelerated amortization of certain CDMO client relationships following loss of key customers, restructuring activities including higher asset impairments and site consolidation charges, and higher third-party legal and advisory costs. Q2 amortization of intangible assets was $65.4 million versus $32.3 million a year earlier.
What is the status of the non-human primate investigations and litigation?
In July 2025 USFWS determined to clear the NHP Shipments for legal entry into the United States, and the DOJ informed the company that both the grand jury and parallel civil investigations had closed. The SEC investigation is ongoing, the securities class action is on appeal at the First Circuit, and two derivative lawsuits are stayed. The company cannot reasonably estimate potential exposure in these matters.
What is the company doing about its capital allocation and strategic direction?
The company repurchased $350.0 million of stock in the first half under a $1.0 billion program, with $549.3 million remaining. Under a Cooperation Agreement with Elliott entered into May 6, 2025, the Board's Strategic Partnership and Capital Allocation Committee is overseeing a comprehensive strategic review, though the filing gives no assurance it will result in any transaction.
How is demand trending across the business segments?
RMS and Manufacturing revenue grew in the quarter, with RMS up 3.3% and Manufacturing up 4.4%, while DSA revenue fell 1.5% on lower volume from cautious client spending. For the six months, DSA revenue declined 1.8%, and DSA operating income fell 14.4%.
How did the company's balance sheet and debt change?
Total debt and finance leases were $2,349.5 million as of June 28, 2025, up from $2,259.0 million at December 28, 2024, with the revolving facility rising to $813.0 million from $714.9 million. Cash and cash equivalents were $182.8 million, and the weighted average interest rate on debt was 4.13%.
06—Continue